Kineta is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease. We show 3 historical shares outstanding datapoints in our KA shares outstanding history coverage, used to compute KA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KA market cap history over the course of time is important for investors
interested in comparing KA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KA versus a peer is one thing; comparing
KA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KA can fluctuate over the course of history.
With this page we aim to empower investors researching KA by allowing them to research the KA market cap history. |
Free KA Email Alerts:
Video: The Importance of Market Cap
